Clinical Trial Update: Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial for early triple-negative breast cancer evaluating a response-guided approach using Iparomlimab and Tuvonralimab in combination with c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Breast Cancer, Neoadjuvant Therapy | Phase 2 | Status: NOT_YET_RECRUITING